¼¼°èÀÇ À¯¹æ¾Ï Ä¡·á ½ÃÀå : ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2025-2034³â)
Breast Cancer Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
»óǰÄÚµå : 1797854
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 130 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 6,813,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,499,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 11,730,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ À¯¹æ¾Ï Ä¡·á ½ÃÀåÀº 2024³â 315¾ï ´Þ·¯·Î Æò°¡µÇ¸ç CAGR 8.5%·Î ¼ºÀåÇØ 2034³â±îÁö 713¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀåÀÇ ¿äÀÎÀº ³ôÀº À¯¹æ¾Ï ÀÌȯÀ², Á¶±â ¹ß°ß ¹× Ä¡·á¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁö°í, Á¤ºÎ³ª ºñ¿µ¸® ´Üü¿¡ ÀÇÇÑ °ËÁø Áö¿øÀÌ ¸¹±â ¶§¹®ÀÔ´Ï´Ù. °ËÁøÀÌ Áõ°¡Çϰí Á¶±â¿¡ ¹ß°ßµÇ´Â »ç·Ê°¡ Áõ°¡ÇÔ¿¡ µû¶ó È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ°í ½ÃÀå ±â¼¼¸¦ Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ °í·ÉÈ­À² »ó½Â, ºñ¸¸, ¾É±â ½¬¿î ¶óÀÌÇÁ½ºÅ¸ÀÏ, µµ½ÃÈ­°¡ À¯¹æ¾Ï À¯º´·ü »ó½Â¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ½ÅÈï±¹ ½ÃÀå¿¡¼­ÀÇ ÀÇ·á Á¢±ÙÀÇ È®´ë°¡ Ä¡·áÀÇ º¸±ÞÀ» ´õ¿í µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. Ç¥ÀûÄ¡·á, È£¸£¸ó¿ä¹ý, ¸é¿ª¿ä¹ý µîÀÇ ¸ÂÃãÇü ÀÇ·áÀÇ Áøº¸°¡ Ä¡·á ¼ºÀûÀ» Çâ»ó½ÃÄÑ ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

À¯¹æ¾Ï Ä¡·á Market-IMG1

À¯¹æ¾Ï Ä¡·á ÁúȯÀÇ ÁøÇàÀ» ¾ïÁ¦Çϰí, Àç¹ßÀ» ¿¹¹æÇϰí, »ýÁ¸À²À» Çâ»ó½ÃŰ´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÑ ÀÏ·ÃÀÇ Ä¡·á°¡ Æ÷ÇԵ˴ϴÙ. Merck, AstraZeneca, Novartis, Pfizer, and F. Hoffmann-La Roche µî ÁÖ¿ä Á¦¾à ȸ»ç´Â ¿¬±¸ °³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖÀ¸¸ç, ƯÈ÷ ÇÁ¸®½ÃÀü Á¾¾ç¿Í ¹ÙÀÌ¿À¸¶Ä¿ ÁÖµµÇü Ä¡·á¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. Á¤ºÎÀÇ °ËÁø ÇÁ·Î±×·¥°ú °è¸ù Ä·ÆäÀÎÀº Á¶±â Áø´ÜÀ» °¡¼ÓÈ­ÇÏ°í ³ª¾Æ°¡ ¼±ÁøÀû Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ½ÅÈï±¹ÀÇ ÇコÄɾî ÀÎÇÁ¶óÀÇ ¼ºÀå°ú »óȯÁ¦µµ °³ÇõÀ» ÅëÇØ º¸´Ù ±¤¹üÀ§ÇÑ Á¢±ÙÀÌ °¡´ÉÇÕ´Ï´Ù. ´ÜÀÏŬ·ÐÇ×ü, ÀúºÐÀÚ ¾ïÁ¦Á¦, ¸é¿ªÁ¾¾ç¾à µî, º¸´Ù Ç¥ÀûÀ» Á¼Èù Ä¡·á·ÎÀÇ ÀüȯÀÌ, ºÎÀÛ¿ëÀ» ¾ïÁ¦Çϸ鼭 È¿´ÉÀ» Çâ»ó½ÃÄÑ, ä¿ëÀ» ÇÑÃþ ´õ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2024³â
¿¹Ãø ¿¬µµ 2025-2034³â
½ÃÀÛ ±Ý¾× 315¾ï ´Þ·¯
¿¹Ãø ±Ý¾× 713¾ï ´Þ·¯
CAGR 8.5%

Ç¥Àû Ä¡·áÁ¦´Â ¾Ï °ü·Ã ¹ÙÀÌ¿À¸¶Ä¿¸¦ Ç¥ÀûÀ¸·Î ÇÏ°í ºÎÀÛ¿ëÀÌ Àû±â ¶§¹®¿¡ 2024³â 214¾ï ´Þ·¯ÀÇ ¸ÅÃâÀ» ±â·ÏÇß½À´Ï´Ù. Ç×ü ¾à¹° º¹ÇÕü, HER2 ¾ïÁ¦Á¦, PARP ¾ïÁ¦Á¦ µîÀÇ Ä¡·á ÇüÅ´ Ãʱ⠴ܰèºÎÅÍ Èı⠴ܰè±îÁöÀÇ Ä¡·á ÇÁ·ÎÅäÄÝ¿¡¼­ ³Î¸® »ç¿ëµË´Ï´Ù. HER2 ³·Àº ÇÏÀ§À¯Çü Ä¡·áÁ¦¿Í AI¸¦ ÅëÇÑ È¯ÀÚ °èÃþÈ­ÀÇ Çõ½ÅÀº ÀÌ ¹üÁÖÀÇ Áö¼ÓÀûÀÎ ½ÃÀå ¸®´õ½ÊÀ» Áö¿øÇÕ´Ï´Ù.

ħÀ±¼º À¯¹æ¾Ï ºÎ¹®Àº 2024³â¿¡ 78.9%ÀÇ Á¡À¯À²À» Â÷ÁöÇϸç, °¡Àå ÀÌȯÀ²ÀÌ ³ôÀº º´ÇüÀÔ´Ï´Ù. ħÀ±¼º À¯°ü¾Ï¸¸À¸·Î ħÀ±¼º Áõ·ÊÀÇ ¾à 80%, À¯¹æ¾Ï Áø´ÜÀÇ ¾à 55%¸¦ Â÷ÁöÇÕ´Ï´Ù. ħÀ±¼º À¯¹æ¾ÏÀº ±× °ø°ÝÀûÀÎ ¼ºÁú°ú À¯°ü¿Ü·ÎÀÇ ÀüÀÌÀÇ °¡´É¼ºÀ¸·ÎºÎÅÍ, Ç¥Àû¾à, SERM µîÀÇ È£¸£¸ó Á¶Á¤¾à, È­Çпä¹ý, ¸é¿ª¿ä¹ý µî Æø³ÐÀº Ä¡·á ¾îÇÁ·ÎÄ¡°¡ ¿ä±¸µÇ¾î °­ÇÑ ÀÓ»ó ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

ºÏ¹ÌÀÇ À¯¹æ¾Ï Ä¡·á ½ÃÀå Á¡À¯À²Àº 2024³â 40.9%·Î ¹Ì±¹°ú ij³ª´Ù°¡ À̲ø°í ÀÖ½À´Ï´Ù. °íµµÀÇ ÇコÄɾî ÀÎÇÁ¶ó, Á¶±â ¹ß°ß¿¡ ´ëÇÑ ÀǽÄÀÇ ³ôÀÌ, ¿Õ¼ºÇÑ ¾Ï ¿¬±¸ ÅõÀÚ, À¯¸®ÇÑ »óȯ Á¦µµ°¡ Ä¡·áÁ¦ ä¿ëÀ» µÞ¹ÞħÇß½À´Ï´Ù. ÀÌ Áö¿ªÀº ½Å¼ÓÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, µ¶ÀÚÀûÀÎ Ä¡·á¹ýÀÇ ³ôÀº º¸±Þ·ü, »õ·Î¿î Ä¡·á¹ýÀÇ ±¤¹üÀ§ÇÑ µµÀÔ µîÀÇ ÇýÅÃÀ» ¹Þ¾Æ ¼¼°è À¯¹æ¾Ï Ä¡·á »óȲ¿¡¼­ÀÇ ¸®´õ½ÊÀ» °­È­Çϰí ÀÖ½À´Ï´Ù.

ÀÌ ¾÷°è¸¦ Çü¼ºÇÏ´Â ÁÖ¿ä ±â¾÷Àº ±â¼ú Çõ½Å°ú ¼¼°è Àü°³¸¦ ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä Á¦¾à ȸ»ç´Â µ¿¹ÝÀÚ Áø´Ü¿¡ ÀÇÇØ ÃÖÀûÈ­µÈ Á¤¹Ð Ç¥Àû Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â ºÐÀÚ ¾ÆÇü¿¡ ÀÇÇÑ È¯ÀÚÀÇ Ãþº°È­¿¡ ÁßÁ¡À» µÓ´Ï´Ù. ¸¹Àº ±â¾÷µéÀÌ Ç×ü ¾à¹° º¹ÇÕü, ÀÌÁ߯¯ÀÌÀû Ç×ü, CDK4/6 ¾ïÁ¦Á¦, ¸é¿ª¿ä¹ýÀÇ Á¶ÇÕ µî ½Å±Ô Ä¡·á¹ýÀÇ ÆÄÀÌÇÁ¶óÀÎÀ» È®ÃæÇÏ°í Æ÷Æ®Æú¸®¿ÀÀÇ Ãæ½ÇÀ» µµ¸ðÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷°úÀÇ Àü·«Àû Àμö, ¶óÀ̼±½Ì °è¾à, Àü·«Àû Á¦ÈÞ·Î Çõ½ÅÀûÀÎ È­ÇÕ¹°°ú »õ·Î¿î R&D Àη¿¡ ´ëÇÑ Á¢±ÙÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ½ÅÈï ½ÃÀåÀ¸·ÎÀÇ ¼¼°è È®ÀåÀº Áö¿ª ÆÇ¸ÅÀÚ ¹× ÀÇ·á ½Ã½ºÅÛ°úÀÇ Á¦ÈÞ¸¦ ÅëÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±â¾÷Àº »óȯÇù»óÀ» Áö¿øÇϱâ À§ÇØ ½ÇÁ¦ ÀÓ»ó½ÃÇè°ú °¡Ä¡¸¦ ¹ÙÅÁÀ¸·Î ÇÏ´Â ¼º°ú¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : ¿ä¹ýº°, 2021-2034³â

Á¦6Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : ¾Ï À¯Çüº°, 2021-2034³â

Á¦7Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : Åõ¿© °æ·Îº°, 2021-2034³â

Á¦8Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : ¿¬·Éº°, 2021-2034³â

Á¦9Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021-2034³â

Á¦10Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : Áö¿ªº°, 2021-2034³â

Á¦11Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Breast Cancer Therapeutics Market was valued at USD 31.5 billion in 2024 and is estimated to grow at a CAGR of 8.5% to reach USD 71.3 billion by 2034. The market growth is attributed to a combination of factors: high incidence of breast cancer, expanded awareness of early detection and treatment, and rising support from government and nonprofit screening initiatives. As screening increases and more cases are identified at earlier stages, demand for effective treatment options rises, supporting the market's momentum. Also, rising rates of aging populations, obesity, sedentary lifestyles, and urbanization are contributing to higher breast cancer prevalence. Expanded health access in developing markets further boosts therapy uptake. Advances in personalized medicine-such as targeted treatments, hormone therapy, and immunotherapy-are enhancing outcomes and fueling market expansion.

Breast Cancer Therapeutics Market - IMG1

Breast cancer therapeutics encompass a spectrum of treatments aimed at controlling disease progression, preventing recurrence, and improving survival. Leading pharmaceutical firms such as Merck, AstraZeneca, Novartis, Pfizer, and F. Hoffmann-La Roche are investing heavily in R&D, particularly focusing on precision oncology and biomarker-driven therapies. Government screening programs and awareness campaigns are accelerating early diagnosis, which in turn drives demand for advanced treatments. Growth in emerging economies' healthcare infrastructure and reimbursement reforms enabling broader access. The shift toward more targeted interventions-including monoclonal antibodies, small-molecule inhibitors, and immuno-oncology agents-is improving efficacy while reducing side effects, further boosting adoption.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$31.5 Billion
Forecast Value$71.3 Billion
CAGR8.5%

The targeted therapies generated USD 21.4 billion in 2024, dominating due to their ability to target cancer-associated biomarkers with fewer adverse reactions. Formats such as antibody-drug conjugates, HER2 inhibitors, and PARP inhibitors are widely adopted across both early- and late-stage treatment protocols. Innovations in HER2 low subtype therapies and AI guided patient stratification support continued market leadership of this category.

The invasive breast cancer segment held 78.9% share in 2024 and is the most prevalent form of disease. Invasive ductal carcinoma alone accounts for about 80% of all invasive cases and roughly 55% of breast cancer diagnoses. Because of its aggressive nature and potential to metastasize beyond the ducts, invasive breast cancer demands broad treatment approaches, including targeted agents, hormone modulators such as SERMs, chemotherapy, and immunotherapies, driving strong clinical demand.

North America Breast Cancer Therapeutics Market held 40.9% share in 2024, with the United States and Canada leading. Advanced healthcare infrastructure, high early detection awareness, strong oncology research investment, and favorable reimbursement systems drove therapeutic adoption. This region benefits from rapid regulatory approvals, high proprietary therapy penetration, and widespread uptake of emerging treatment modalities, reinforcing its leadership in the global breast cancer therapeutics landscape.

Major companies shaping this industry include Pfizer, F. Hoffmann-La Roche, Merck, AstraZeneca, Novartis, and Eli Lilly, driving innovation and global reach. Leading pharmaceutical players are focusing heavily on patient stratification by molecular subtype, enabling precision-targeted therapies optimized with companion diagnostics. Many firms are expanding pipelines in novel modalities such as antibody-drug conjugates, bispecific antibodies, CDK4/6 inhibitors, and immunotherapy combinations to strengthen portfolio depth. Strategic acquisitions, licensing agreements, and strategic partnerships with biotech firms accelerate access to innovative compounds and emerging R&D talent. Global expansion into emerging markets is being achieved through collaborations with regional distributors and healthcare systems. Additionally, firms invest in real-world studies and value-based outcomes to support reimbursement negotiations.

Table of Contents

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2024

Chapter 5 Market Estimates and Forecast, By Therapy, 2021 - 2034 ($ Mn)

Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 - 2034 ($ Mn)

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

Chapter 8 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

Chapter 11 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â